Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin

Overview of attention for article published in Molecular Cancer, November 2013

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

blogs: 1 blog

patent: 10 patents

Citations

dimensions_citation: 25 Dimensions

Readers on

mendeley: 25 Mendeley

Summary Blogs Patents Dimensions citations

So far, Altmetric has seen 1 blog post.

Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin

Science Alerts Social Network, 20 Nov 2013

PAM4, an antibody that has high specificity for pancreatic ductal adenocarcinoma (PDAC), compared to normal pancreas, benign…

This page shows the most recent blog posts that mention this research output.

Click here to find out how to access more activity.